In episode 13 Ben chats with Dr. Alison Cox, BCBA-D, about her research on psychotropic medication including effects on behavioural function, side effects and more!


Continuing Education Units (CEUs):


Show Notes:



  • Cox, A., Leung, J., Morgan, M-C & Anderson, B. (2021). Examining research trends in the treatment of adults with problem behavior and intellectual and developmental disabilities: A brief review. Behavioral Development, 26(1), 14-28.
  • Cox, A. D. & Virues‐Ortega, J. (2016). Interactions between behavior function and psychotropic medication. Journal of Applied Behavior Analysis, 49, 85-104. 
  • Crosland, K. A., Zarcone, J. R., Lindauer, S. E., Valdovinos, M. G., Zarcone, T. J., Hellings, J. A., & Schroeder, S. R. (2003). Use of functional analysis methodology in the evaluation of medication effects. Journal of Autism and Developmental Disorders, 33(3), 271-279. 
  • Fisher, W., Piazza, C. C., Page, T. J. (1989). Assessing independent and interactive effects of behavioral and pharmacologic interventions for a client with dual diagnoses. Journal of Behavior Therapy and Experimental Psychiatry, 20(3), 241-250. 
  • Northup, J., Fusilier, I., Swanson, V., Huete, J., Bruce, T., Freeland, J., Gulley, V. & Edwards, S. (1999). Further analysis of the separate and interactive effects of methylphenidate and common classroom contingencies. Journal of Applied Behavior Analysis, 32, 35-50. 
  • Northup, J., Fusilier, I., Swanson, V., Roane, H. & Borrero, J. (1997). An evaluation of methylphenidate as a potential establishing operation for some common classroom reinforcers. Journal of Applied Behavior Analysis, 30, 615-625. 
  • Rapp, J. T., Swanson, G., Dornbusch, K. (2007). Temporary increases in problem behavior and sleep disruption following decreases in medication: A descriptive analysis of conditional rates. Behavior Modification, 31, 825-846.
  • Valdovinos, M. G. (2019). Psychotropic medication in intellectual and developmental disabilities: Patterns of use and recommendations for monitoring effects. Current Developmental Disorders Reports, 6, 195–201.
  • Valdovinos, M. G., Caruso, M., Roberts, C., Kim, G., Kennedy, C. H., Bodfish, J. (2005). Medical and behavioral symptoms as potential medication side effects in adults with developmental disabilities. American Journal of Mental Retardation, 110(3), 164-170.<164:MABSAP>2.0.CO;2
  • Valdovinos, M. G., Schieber, E., McMahon, M. et al. (2017). Adverse side effects of psychotropic medication and challenging behavior: Pilot work assessing impact. Journal of Developmental and Physical Disabilities, 29, 969-982.
  • van Haaren, F. & Weeden, M. (2013). Some guidelines for conducting research in applied behavioral pharmacology. Journal of Applied Behavior Analysis, 46, 498-506.
  • Zarcone, J. R., Lindauer, S. E., Morse, P. S., Crosland, K. A., Valdovinos, M. G., McKerchar, T. L., Matthew Reese, R., Hellings, J. A., & Schroeder, S. R. (2004). Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. American Journal on Mental Retardation, 109(4), 310-321.<310:EORODB>2.0.CO;2 
Share | Download(Loading)
Podbean App

Play this podcast on Podbean App